B-Cell Lymphomas: Optimizing Treatment with Small Molecule Inhibitors
This information was originally presented at the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida, from March 31 – April 2, 2016.
Target Audience
This activity is designed to meet the educational needs of medical, surgical, and radiation oncologists; nurses; physician assistants; pharmacists; pathologists; and other healthcare professionals who manage patients with cancer.
Learning Objectives
Following this activity, participants should be able to:
- Name the special considerations associated with the use of currently approved small molecule inhibitors and develop an individualized treatment plan for patients with CLL and B-cell lymphomas
- Discuss the mechanism action, safety and efficacy of novel small molecule inhibitors and their potential role in the management of CLL and B-cell lymphomas
Jeffrey Jones, MD, MPH
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
Barbara Pro, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics.
The faculty listed below have disclosed the following relevant financial relationships:
Jeffrey Jones, MD, MPH
Abbott Laboratories: Grant/Research Support; Scientific Advisor
Celgene Corporation: Scientific Advisor
Genentech, Inc.: Grant/Research Support; Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Pharmacyclics: Grant/Research Support; Scientific Advisor
Barbara Pro, MD
Celgene Corporation: Consulting Fees; Honoraria
Takeda: Honoraria
NCCN Staff Disclosures
The activity planning staff listed below has no relevant financial relationships to disclose:
Robert W. Carlson, MD; Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser
The activity planning staff listed below has disclosed the following relevant financial relationships:
Mercedes De La Hoz
Pfizer Inc.: Other financial benefit
The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:
Mary Dwyer, MS; Hema Sundar, PhD
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
National Comprehensive Cancer Network designates this activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Release date: May 27, 2016
Expiration date: March 1, 2017
Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 1.08 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.
Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.
Release date: May 27, 2016
Expiration date: March 1, 2017
Pharmacists
National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
Type of Activity: Knowledge
National Comprehensive Cancer Network designates this continuing education activity for 1.00 contact hour (0.10 CEUs) of continuing education credit in states that recognize ACPE accredited providers.
Universal Activity Number: 0836-0000-16-067-H01-P
Release date: May 27, 2016
Expiration date: March 1, 2017
Available Credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.08 ANCC contact hours
- 1.00 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
- Adobe Reader or other PDF reader software for certificate viewing/printing